289 related articles for article (PubMed ID: 26619245)
1. Pancreatic cancer: Update on immunotherapies and algenpantucel-L.
McCormick KA; Coveler AL; Rossi GR; Vahanian NN; Link C; Chiorean EG
Hum Vaccin Immunother; 2016 Mar; 12(3):563-75. PubMed ID: 26619245
[TBL] [Abstract][Full Text] [Related]
2. Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.
Coveler AL; Rossi GR; Vahanian NN; Link C; Chiorean EG
Immunotherapy; 2016 Feb; 8(2):117-25. PubMed ID: 26787078
[TBL] [Abstract][Full Text] [Related]
3. Novel pancreatic cancer vaccines could unleash the army within.
Springett GM
Cancer Control; 2014 Jul; 21(3):242-6. PubMed ID: 24955709
[TBL] [Abstract][Full Text] [Related]
4. A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
Hewitt DB; Nissen N; Hatoum H; Musher B; Seng J; Coveler AL; Al-Rajabi R; Yeo CJ; Leiby B; Banks J; Balducci L; Vaccaro G; LoConte N; George TJ; Brenner W; Elquza E; Vahanian N; Rossi G; Kennedy E; Link C; Lavu H
Ann Surg; 2022 Jan; 275(1):45-53. PubMed ID: 33630475
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
6. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
Hardacre JM; Mulcahy M; Small W; Talamonti M; Obel J; Krishnamurthi S; Rocha-Lima CS; Safran H; Lenz HJ; Chiorean EG
J Gastrointest Surg; 2013 Jan; 17(1):94-100; discussion p. 100-1. PubMed ID: 23229886
[TBL] [Abstract][Full Text] [Related]
7. Immune Therapy in Pancreatic Cancer: Now and the Future?
Zhang Y; Choi M
Rev Recent Clin Trials; 2015; 10(4):317-25. PubMed ID: 26374557
[TBL] [Abstract][Full Text] [Related]
8. Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.
Kinkead HL; Hopkins A; Lutz E; Wu AA; Yarchoan M; Cruz K; Woolman S; Vithayathil T; Glickman LH; Ndubaku CO; McWhirter SM; Dubensky TW; Armstrong TD; Jaffee EM; Zaidi N
JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333318
[TBL] [Abstract][Full Text] [Related]
9. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation.
Lutz E; Yeo CJ; Lillemoe KD; Biedrzycki B; Kobrin B; Herman J; Sugar E; Piantadosi S; Cameron JL; Solt S; Onners B; Tartakovsky I; Choi M; Sharma R; Illei PB; Hruban RH; Abrams RA; Le D; Jaffee E; Laheru D
Ann Surg; 2011 Feb; 253(2):328-35. PubMed ID: 21217520
[TBL] [Abstract][Full Text] [Related]
10. MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy.
Gautam SK; Kumar S; Dam V; Ghersi D; Jain M; Batra SK
Semin Immunol; 2020 Feb; 47():101391. PubMed ID: 31952903
[TBL] [Abstract][Full Text] [Related]
11. Emerging trends in the immunotherapy of pancreatic cancer.
Banerjee K; Kumar S; Ross KA; Gautam S; Poelaert B; Nasser MW; Aithal A; Bhatia R; Wannemuehler MJ; Narasimhan B; Solheim JC; Batra SK; Jain M
Cancer Lett; 2018 Mar; 417():35-46. PubMed ID: 29242097
[TBL] [Abstract][Full Text] [Related]
12. Potential targets for pancreatic cancer immunotherapeutics.
Dodson LF; Hawkins WG; Goedegebuure P
Immunotherapy; 2011 Apr; 3(4):517-37. PubMed ID: 21463193
[TBL] [Abstract][Full Text] [Related]
13. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.
Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L
J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for pancreatic cancer: current concepts.
Kaufman HL; Di Vito J; Hörig H
Hematol Oncol Clin North Am; 2002 Feb; 16(1):159-97, viii. PubMed ID: 12063825
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapeutic Approaches in Pancreatic Adenocarcinoma: Current Status and Future Perspectives.
Yee NS
Curr Mol Pharmacol; 2016; 9(3):231-241. PubMed ID: 26177643
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy and Prevention of Pancreatic Cancer.
Morrison AH; Byrne KT; Vonderheide RH
Trends Cancer; 2018 Jun; 4(6):418-428. PubMed ID: 29860986
[TBL] [Abstract][Full Text] [Related]
17. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for pancreatic ductal adenocarcinoma.
Carpenter E; Nelson S; Bednar F; Cho C; Nathan H; Sahai V; di Magliano MP; Frankel TL
J Surg Oncol; 2021 Mar; 123(3):751-759. PubMed ID: 33595893
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy for pancreatic cancer.
Tseng JF; Mulligan RC
Surg Oncol Clin N Am; 2002 Jul; 11(3):537-69. PubMed ID: 12487056
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.
Lutz ER; Wu AA; Bigelow E; Sharma R; Mo G; Soares K; Solt S; Dorman A; Wamwea A; Yager A; Laheru D; Wolfgang CL; Wang J; Hruban RH; Anders RA; Jaffee EM; Zheng L
Cancer Immunol Res; 2014 Jul; 2(7):616-31. PubMed ID: 24942756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]